[144] Idexx Laboratories Inc SEC Filing
Form 144 notice for IDEXX Laboratories (IDXX) reports a proposed sale of 407 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $264,533.53. The filing lists the company's outstanding shares as 80,004,694, so the proposed sale represents approximately 0.00051% of outstanding stock. The acquisition history provided shows the shares originated from multiple Employee Stock Purchase Plan purchases and a Restricted Stock grant, with acquisition dates ranging from 06/30/2021 through 03/29/2024. The filer certifies they are not aware of undisclosed material adverse information and uses Morgan Stanley as the executing broker. The proposed approximate sale date is 08/12/2025.
Avviso Form 144 relativo a IDEXX Laboratories (IDXX) segnala una proposta di vendita di 407 azioni ordinarie tramite Morgan Stanley Smith Barney LLC sul NASDAQ, per un valore di mercato complessivo di $264,533.53. Il deposito indica che le azioni in circolazione sono 80,004,694, quindi la vendita proposta rappresenta circa 0.00051% del capitale sociale. La cronologia delle acquisizioni mostra che le azioni derivano da più acquisti nell'ambito dell'Employee Stock Purchase Plan e da una concessione di Restricted Stock, con date di acquisizione dal 06/30/2021 al 03/29/2024. Il dichiarante certifica di non essere a conoscenza di informazioni riservate sfavorevoli non divulgate e indica Morgan Stanley come broker esecutore. La data approssimativa proposta per la vendita è il 08/12/2025.
Aviso Form 144 para IDEXX Laboratories (IDXX) informa una propuesta de venta de 407 acciones ordinarias a través de Morgan Stanley Smith Barney LLC en el NASDAQ, con un valor de mercado agregado de $264,533.53. La presentación indica que las acciones en circulación son 80,004,694, por lo que la venta propuesta representa aproximadamente el 0.00051% del capital social. El historial de adquisición muestra que las acciones provienen de varias compras del Employee Stock Purchase Plan y de una concesión de Restricted Stock, con fechas de adquisición desde el 06/30/2021 hasta el 03/29/2024. El declarante certifica que no tiene conocimiento de información adversa material no divulgada y utiliza a Morgan Stanley como corredor ejecutor. La fecha aproximada propuesta para la venta es el 08/12/2025.
IDEXX Laboratories (IDXX)에 대한 Form 144 통지는 Morgan Stanley Smith Barney LLC를 통해 NASDAQ에서 407주의 보통주 매각을 제안했으며, 총 시가총액은 $264,533.53라고 보고합니다. 신고서에는 발행주식수가 80,004,694로 기재되어 있어 제안된 매각이 발행주식의 약 0.00051%에 해당함을 나타냅니다. 취득 이력에 따르면 해당 주식은 여러 차례의 Employee Stock Purchase Plan 구매와 Restricted Stock 부여에서 발생했으며, 취득일은 06/30/2021부터 03/29/2024까지입니다. 제출자는 공시되지 않은 중대한 불리한 정보가 없음을 증명하고 있으며, 실행 중개인으로 Morgan Stanley를 지정했습니다. 제안된 대략적인 매각일은 08/12/2025입니다.
Avis Form 144 pour IDEXX Laboratories (IDXX) signale une proposition de vente de 407 actions ordinaires par l'intermédiaire de Morgan Stanley Smith Barney LLC sur le NASDAQ, pour une valeur marchande globale de $264,533.53. Le dépôt indique que le nombre d'actions en circulation est de 80,004,694, de sorte que la vente proposée représente environ 0.00051% du capital social. L'historique des acquisitions montre que les actions proviennent de plusieurs achats dans le cadre du Employee Stock Purchase Plan et d'une attribution de Restricted Stock, avec des dates d'acquisition allant du 06/30/2021 au 03/29/2024. Le déclarant certifie ne pas avoir connaissance d'informations défavorables matérielles non divulguées et utilise Morgan Stanley comme courtier exécutant. La date approximative proposée pour la vente est le 08/12/2025.
Form 144-Mitteilung für IDEXX Laboratories (IDXX) meldet einen vorgeschlagenen Verkauf von 407 Stammaktien über Morgan Stanley Smith Barney LLC an der NASDAQ mit einem Gesamtmarktwert von $264,533.53. Die Einreichung nennt die ausstehenden Aktien mit 80,004,694, sodass der vorgeschlagene Verkauf etwa 0.00051% des ausstehenden Kapitals ausmacht. Die Erwerbshistorie zeigt, dass die Aktien aus mehreren Käufen im Rahmen des Employee Stock Purchase Plan und einer Zuteilung von Restricted Stock stammen, mit Erwerbsdaten vom 06/30/2021 bis zum 03/29/2024. Der Einreichende bestätigt, dass ihm keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind, und benennt Morgan Stanley als ausführenden Broker. Das voraussichtliche ungefähre Verkaufsdatum ist der 08/12/2025.
- Complete disclosure of broker, exchange, proposed sale date, and aggregate market value
- Acquisition history provided showing Employee Stock Purchase Plan and Restricted Stock origins
- Filer certification that no undisclosed material adverse information is known
- None.
Insights
TL;DR: Small insider sale notice: 407 shares valued at $264,533.53—negligible versus 80,004,694 outstanding shares.
The Form 144 documents a planned sale under Rule 144 for 407 common shares using Morgan Stanley as broker with an aggregate value of $264,533.53. Given the stated 80,004,694 shares outstanding, the sale equals roughly 0.00051% of the float, indicating the transaction is immaterial to company capital structure. The filing includes a clear acquisition record showing multiple Employee Stock Purchase Plan purchases and a Restricted Stock grant, and the filer affirms no undisclosed material adverse information. From a market-impact perspective, the notice signals compliance rather than a material shift in ownership.
TL;DR: Compliance-focused filing: disclosure of provenance and broker details; sale size is trivial relative to outstanding shares.
The Form 144 provides the necessary disclosure elements: broker name (Morgan Stanley Smith Barney LLC), exchange (NASDAQ), proposed sale date (08/12/2025), and a detailed acquisition history (ESPP and Restricted Stock entries). The filer also makes the standard certification regarding material non-public information. These items demonstrate adherence to disclosure rules for an insider sale; nothing in the filing raises governance or compliance concerns based on the information presented.
Avviso Form 144 relativo a IDEXX Laboratories (IDXX) segnala una proposta di vendita di 407 azioni ordinarie tramite Morgan Stanley Smith Barney LLC sul NASDAQ, per un valore di mercato complessivo di $264,533.53. Il deposito indica che le azioni in circolazione sono 80,004,694, quindi la vendita proposta rappresenta circa 0.00051% del capitale sociale. La cronologia delle acquisizioni mostra che le azioni derivano da più acquisti nell'ambito dell'Employee Stock Purchase Plan e da una concessione di Restricted Stock, con date di acquisizione dal 06/30/2021 al 03/29/2024. Il dichiarante certifica di non essere a conoscenza di informazioni riservate sfavorevoli non divulgate e indica Morgan Stanley come broker esecutore. La data approssimativa proposta per la vendita è il 08/12/2025.
Aviso Form 144 para IDEXX Laboratories (IDXX) informa una propuesta de venta de 407 acciones ordinarias a través de Morgan Stanley Smith Barney LLC en el NASDAQ, con un valor de mercado agregado de $264,533.53. La presentación indica que las acciones en circulación son 80,004,694, por lo que la venta propuesta representa aproximadamente el 0.00051% del capital social. El historial de adquisición muestra que las acciones provienen de varias compras del Employee Stock Purchase Plan y de una concesión de Restricted Stock, con fechas de adquisición desde el 06/30/2021 hasta el 03/29/2024. El declarante certifica que no tiene conocimiento de información adversa material no divulgada y utiliza a Morgan Stanley como corredor ejecutor. La fecha aproximada propuesta para la venta es el 08/12/2025.
IDEXX Laboratories (IDXX)에 대한 Form 144 통지는 Morgan Stanley Smith Barney LLC를 통해 NASDAQ에서 407주의 보통주 매각을 제안했으며, 총 시가총액은 $264,533.53라고 보고합니다. 신고서에는 발행주식수가 80,004,694로 기재되어 있어 제안된 매각이 발행주식의 약 0.00051%에 해당함을 나타냅니다. 취득 이력에 따르면 해당 주식은 여러 차례의 Employee Stock Purchase Plan 구매와 Restricted Stock 부여에서 발생했으며, 취득일은 06/30/2021부터 03/29/2024까지입니다. 제출자는 공시되지 않은 중대한 불리한 정보가 없음을 증명하고 있으며, 실행 중개인으로 Morgan Stanley를 지정했습니다. 제안된 대략적인 매각일은 08/12/2025입니다.
Avis Form 144 pour IDEXX Laboratories (IDXX) signale une proposition de vente de 407 actions ordinaires par l'intermédiaire de Morgan Stanley Smith Barney LLC sur le NASDAQ, pour une valeur marchande globale de $264,533.53. Le dépôt indique que le nombre d'actions en circulation est de 80,004,694, de sorte que la vente proposée représente environ 0.00051% du capital social. L'historique des acquisitions montre que les actions proviennent de plusieurs achats dans le cadre du Employee Stock Purchase Plan et d'une attribution de Restricted Stock, avec des dates d'acquisition allant du 06/30/2021 au 03/29/2024. Le déclarant certifie ne pas avoir connaissance d'informations défavorables matérielles non divulguées et utilise Morgan Stanley comme courtier exécutant. La date approximative proposée pour la vente est le 08/12/2025.
Form 144-Mitteilung für IDEXX Laboratories (IDXX) meldet einen vorgeschlagenen Verkauf von 407 Stammaktien über Morgan Stanley Smith Barney LLC an der NASDAQ mit einem Gesamtmarktwert von $264,533.53. Die Einreichung nennt die ausstehenden Aktien mit 80,004,694, sodass der vorgeschlagene Verkauf etwa 0.00051% des ausstehenden Kapitals ausmacht. Die Erwerbshistorie zeigt, dass die Aktien aus mehreren Käufen im Rahmen des Employee Stock Purchase Plan und einer Zuteilung von Restricted Stock stammen, mit Erwerbsdaten vom 06/30/2021 bis zum 03/29/2024. Der Einreichende bestätigt, dass ihm keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind, und benennt Morgan Stanley als ausführenden Broker. Das voraussichtliche ungefähre Verkaufsdatum ist der 08/12/2025.
FAQ
What does the IDEXX (IDXX) Form 144 report?
When is the proposed sale date on the IDXX Form 144?
How significant is the proposed sale relative to IDEXX's outstanding shares?
What is the origin of the shares being sold in the IDXX Form 144?
Who is the executing broker named in the Form 144 for IDXX?
